Diskussion zu CytoSorbents Corporation (Seite 423)
eröffnet am 20.05.09 17:22:57 von
neuester Beitrag 30.04.24 22:46:00 von
neuester Beitrag 30.04.24 22:46:00 von
Beiträge: 4.238
ID: 1.150.520
ID: 1.150.520
Aufrufe heute: 0
Gesamt: 690.210
Gesamt: 690.210
Aktive User: 0
ISIN: US23283X2062 · WKN: A12GDU · Symbol: CTSO
0,8780
EUR
+9,00 %
+0,0725 EUR
Letzter Kurs 17.05.24 Quotrix Düsseldorf
Neuigkeiten
09.05.24 · globenewswire  |
02.05.24 · globenewswire |
26.04.24 · globenewswire |
17.04.24 · globenewswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8600 | +36,51 | |
| 0,8600 | +17,95 | |
| 1,2900 | +12,17 | |
| 0,9676 | +11,69 | |
| 13,970 | +10,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9080 | -14,82 | |
| 3,0100 | -17,31 | |
| 0,6000 | -18,92 | |
| 1,4500 | -21,62 | |
| 3,5800 | -24,79 |
Beitrag zu dieser Diskussion schreiben
Feedback
Das Medasorb nicht so bekannt ist sieht man auch daran das trotz dieser Nachricht den Hype nicht mitgemacht hat ..
CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak
Wednesday May 6, 2009, 8:30 am EDT
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--May 6, 2009 -- CytoSorbents, Inc. comments on the current swine flu outbreak and highlights the urgent need for improved therapies for influenza and other respiratory viruses. In particular, potentially virulent pathogens such as avian flu (H5N1 subtype), swine flu (H1N1 subtype), and the SARS virus can quickly kill a large percentage of those infected. According to the Centers for Disease Control, normal seasonal influenza afflicts 15-60 million people in the United States each year, hospitalizing more than 200,000, and directly contributing to the deaths of 36,000 people annually. Although these numbers are significant, in contrast, the 1918 Spanish influenza pandemic infected an estimated one third of the world population, killing nearly 50 million people. Highly virulent flu strains have the ability to evade neutralization by the immune system, leading to a prolonged and intense infection that can lead to severe sepsis and death. Although the virus itself has destructive capability, the body's own aggressive immune response and "cytokine storm" are recognized as leading drivers of mortality in these patients. Cytokines are normally helpful proteins that control the immune system. In severe sepsis due to influenza, however, cytokines are often produced in excessive, toxic quantities leading to acute respiratory distress syndrome (severe lung inflammation), organ failure, and numerous complications that often result in death. Anti-viral therapy such as Tamiflu(TM), Relenza(TM) and amantadine may slow viral infection if used early enough and if resistance is not an issue. But given the major role that cytokine storm is believed to play in the pathogenesis of these deadly viruses, more options are needed to directly address this critical issue now.
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments. In animal bacterial sepsis studies performed at the University of Pittsburgh Medical Center, CytoSorb(TM) significantly improved hemodynamic stability and short-term survival while simultaneously reducing cytokine levels with a single treatment, compared to sham-treated control animals. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. All of these patients are on mechanical ventilation and have either acute lung injury or acute respiratory distress syndrome, similar to what is expected to be seen in a major influenza pandemic. The results from this study may pave the way for the potential future use of CytoSorb(TM) in the treatment of critically ill influenza patients.
CytoSorbents Chief Executive Officer, Phillip Chan, MD, PhD, stated, "It has been well-accepted that severe sepsis, caused by either bacteria or viruses, has two important facets. One is the infectious agent that can be treated with antibiotics or antiviral medications. But the other is the body's unregulated immune system and cytokine storm that causes much of the organ damage and death in patients with sepsis. Little exists to treat this major problem. CytoSorb(TM) is a powerful technology that could fill this gap."
Dr. Chan continued, "The alarm raised by the current swine flu outbreak demonstrates how vulnerable we are to medical emergencies such as these, be they natural or man-made. In particular, it has highlighted a key weakness in our armamentarium to treat severe infection -- the inability to effectively address cytokine storm. Although CytoSorb(TM) is currently an investigational device and its applicability in influenza remains to be seen, it has the clear potential to be a leading therapy to treat cytokine storm and make a real difference in getting patients well."
Tamiflu(TM) and Relenza(TM) are trademarks of Roche Holding AG and GlaxoSmithKline plc, respectively
CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak
Wednesday May 6, 2009, 8:30 am EDT
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--May 6, 2009 -- CytoSorbents, Inc. comments on the current swine flu outbreak and highlights the urgent need for improved therapies for influenza and other respiratory viruses. In particular, potentially virulent pathogens such as avian flu (H5N1 subtype), swine flu (H1N1 subtype), and the SARS virus can quickly kill a large percentage of those infected. According to the Centers for Disease Control, normal seasonal influenza afflicts 15-60 million people in the United States each year, hospitalizing more than 200,000, and directly contributing to the deaths of 36,000 people annually. Although these numbers are significant, in contrast, the 1918 Spanish influenza pandemic infected an estimated one third of the world population, killing nearly 50 million people. Highly virulent flu strains have the ability to evade neutralization by the immune system, leading to a prolonged and intense infection that can lead to severe sepsis and death. Although the virus itself has destructive capability, the body's own aggressive immune response and "cytokine storm" are recognized as leading drivers of mortality in these patients. Cytokines are normally helpful proteins that control the immune system. In severe sepsis due to influenza, however, cytokines are often produced in excessive, toxic quantities leading to acute respiratory distress syndrome (severe lung inflammation), organ failure, and numerous complications that often result in death. Anti-viral therapy such as Tamiflu(TM), Relenza(TM) and amantadine may slow viral infection if used early enough and if resistance is not an issue. But given the major role that cytokine storm is believed to play in the pathogenesis of these deadly viruses, more options are needed to directly address this critical issue now.
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments. In animal bacterial sepsis studies performed at the University of Pittsburgh Medical Center, CytoSorb(TM) significantly improved hemodynamic stability and short-term survival while simultaneously reducing cytokine levels with a single treatment, compared to sham-treated control animals. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. All of these patients are on mechanical ventilation and have either acute lung injury or acute respiratory distress syndrome, similar to what is expected to be seen in a major influenza pandemic. The results from this study may pave the way for the potential future use of CytoSorb(TM) in the treatment of critically ill influenza patients.
CytoSorbents Chief Executive Officer, Phillip Chan, MD, PhD, stated, "It has been well-accepted that severe sepsis, caused by either bacteria or viruses, has two important facets. One is the infectious agent that can be treated with antibiotics or antiviral medications. But the other is the body's unregulated immune system and cytokine storm that causes much of the organ damage and death in patients with sepsis. Little exists to treat this major problem. CytoSorb(TM) is a powerful technology that could fill this gap."
Dr. Chan continued, "The alarm raised by the current swine flu outbreak demonstrates how vulnerable we are to medical emergencies such as these, be they natural or man-made. In particular, it has highlighted a key weakness in our armamentarium to treat severe infection -- the inability to effectively address cytokine storm. Although CytoSorb(TM) is currently an investigational device and its applicability in influenza remains to be seen, it has the clear potential to be a leading therapy to treat cytokine storm and make a real difference in getting patients well."
Tamiflu(TM) and Relenza(TM) are trademarks of Roche Holding AG and GlaxoSmithKline plc, respectively
Antwort auf Beitrag Nr.: 37.229.446 von TyphoonRally am 21.05.09 21:29:03@TR
Du schreibst so einen Schwachsinn hast du etwa viel geld mit MSBT verloren ?
Bei 3$ hätte ich niemals die Aktie gekauft aber ich bin bei 7 cent eingestiegen um bei 3$ verkaufen zu können
.
..
Medasorb schließt im grünen Bereich unter Rekordvolumen !
Du schreibst so einen Schwachsinn hast du etwa viel geld mit MSBT verloren ?
Bei 3$ hätte ich niemals die Aktie gekauft aber ich bin bei 7 cent eingestiegen um bei 3$ verkaufen zu können
...
Medasorb schließt im grünen Bereich unter Rekordvolumen !
Antwort auf Beitrag Nr.: 37.229.087 von traumstrand am 21.05.09 20:43:27Das Cytosorb kann garnicht funktionieren, weil es nicht existiert. Würde es existieren, dann hätte man es uns längst präsentiert.
Eine von vielen OTC-Klitschen die langfristig bei 0,0001 enden.
Die Aktie ist innerhalb von 3 Jahren von 3$ auf 0,03$ Gefallen... 2012 ist die Aktie wahrscheinlich nur noch 0,0003-0,0001 wert. Es ist einfach nichts dran an der Story.
Eine von vielen OTC-Klitschen die langfristig bei 0,0001 enden.
Die Aktie ist innerhalb von 3 Jahren von 3$ auf 0,03$ Gefallen... 2012 ist die Aktie wahrscheinlich nur noch 0,0003-0,0001 wert. Es ist einfach nichts dran an der Story.
Antwort auf Beitrag Nr.: 37.225.378 von TyphoonRally am 21.05.09 11:07:46@ Typhoon: Das Posting ist Blödsinn!
Das Cytosorb funktioniert im Prinzip eher wie ein Dialysegerät, nur daß damit nicht Nierengifte ausgewaschen werden, sondern die Zytokine, die die Sepsis verschlimmern sollen. Wenn Du Bilder vergleichen willst, such mal nach "Dialysemembrane" z.B. von FMC.
Das Cytosorb funktioniert im Prinzip eher wie ein Dialysegerät, nur daß damit nicht Nierengifte ausgewaschen werden, sondern die Zytokine, die die Sepsis verschlimmern sollen. Wenn Du Bilder vergleichen willst, such mal nach "Dialysemembrane" z.B. von FMC.
Hier wird der vorgang etwas näher erklärt ..
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments.
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments.
Trading Spotlight
Antwort auf Beitrag Nr.: 37.223.943 von traumstrand am 20.05.09 23:51:14Von Milliardenmarkt für diese spezielle Anwendung würde ich nicht unbedingt sprechen. Z.B. gibt es das Spezialmedikament "XIGRIS" von Lilly, das kostet pro Anwendung locker 20.000 €, scheint relativ gut zu funktionieren und hat definitiv deutlich weniger als 500 Mio USD Jahresumsatz weltweit (genauer Zahlen konnte ich nicht finden, könnten vielleicht auch nur 50 Mio. sein...).
Xigris ist ein Flop und zwar deshalb weil es nur bei bestimmten Sepsis kranken eingesetzt werden darf , außerdem waren die PIII Daten damals nicht gerade überzeugend demnach ist Xigris nur minimal besser als Placebo und deshalb sein geld nicht wert .
Bei Cytosorb handelt es sich um ein art "Filter" um es vereinfacht auszudrücken und ich finde die Technik dahinter sehr interessant .
Xigris ist ein Flop und zwar deshalb weil es nur bei bestimmten Sepsis kranken eingesetzt werden darf , außerdem waren die PIII Daten damals nicht gerade überzeugend demnach ist Xigris nur minimal besser als Placebo und deshalb sein geld nicht wert .
Bei Cytosorb handelt es sich um ein art "Filter" um es vereinfacht auszudrücken und ich finde die Technik dahinter sehr interessant .
Antwort auf Beitrag Nr.: 37.225.223 von TyphoonRally am 21.05.09 10:44:29
UB-Designed Ventilator Can Safely Sedate ICU Patients for Less
http://www.buffalo.edu/news/9926
Zum Vergleich Medasorb, Sytosorb
Lasst euch nicht ver...!
UB-Designed Ventilator Can Safely Sedate ICU Patients for Less
http://www.buffalo.edu/news/9926
Zum Vergleich Medasorb, Sytosorb
Lasst euch nicht ver...!
Antwort auf Beitrag Nr.: 37.225.191 von TyphoonRally am 21.05.09 10:38:47Das Gerät auf der Homepage kam mir verdächtig vor und es ist... ein Beatmungsgerät.
Antwort auf Beitrag Nr.: 37.225.114 von TyphoonRally am 21.05.09 10:27:39Da es angeblich schon an Patienten getestet wurde/wird sollte es doch zumindest mal paar fotos von dem Gerät geben.
Antwort auf Beitrag Nr.: 37.223.943 von traumstrand am 20.05.09 23:51:14Diese ganzen Studien sind irreführend!
Die meisten OTC-Pommesbudden kaufen/mieten sich ein Gerät kleben ihr Logo drauf und schon wurde das Rad neu erfunden...
Die meisten OTC-Pommesbudden kaufen/mieten sich ein Gerät kleben ihr Logo drauf und schon wurde das Rad neu erfunden...
Durchsuchen
